EVALUATION OF THE ORAL ANTIMITOTIC, ABT-751, ALONE AND IN COMBINATION AN ANTIANGIOGENIC PEPTIDE OF THROMBOSPONDIN-1, ABT-510, IN DOGS WITH LYMPHOMA
M Silver, T Rusk, C Khanna, Animal Clinical Investigation, Bethesda, Maryland 20817
E-mail Michele Silver
Introduction: Previous studies defined the MTD of ABT-751 in dogs with lymphoma to be 350 mg/m2. Dose limiting toxicities (DLT) were gastrointestinal, including vomiting and diarrhea. Early evidence of clinical activity was observed at this dose. ABT-510, an oral antiangiogenic agent has resulted in efficacy in open-label treatment of dogs with a variety of cancers, including lymphoma.
Methods: Prospective studies of single-agent ABT-751 or in combination with ABT-510 were undertaken in dogs with lymphoma, most of whom had received previous chemotherapy. The dose of ABT-751 was 350mg/m2 PO QD for 7 days, then EOD. ABT-510 was given at 0.5mg/kg SQ BID starting 24 hours after the first dose of ABT-751. Primary endpoints included response rate, response duration, time to progression, and toxicity. Secondary endpoints included pharmacokinetics and changes in circulating endothelial cells.
Results: Treatment with single agent ABT-751 resulted DLT in 4/19 (21.0%) dogs. DLT was observed in 9/25 (36.0%) dogs treated with combination therapy. Cytopenias were observed in 3 dogs treated with combination therapy. No cytopenias were observed in dogs treated with ABT-751 alone. In the treatment-received population, which included dogs on study for at least 7 days, clinical responses were seen in 3/15 (20.0%) treated with ABT751 and 8/20 (40.0%) treated with ABT-751 and ABT-510. Response duration ranged from 8-111 days.
Conclusion: Though small study numbers were evaluated, response rate was higher for combination ABT-751 and ABT-510 versus ABT-751 alone. Toxicity profiles were similar for combination therapy and single-agent ABT-751. No previous toxicity has been observed in over 300 dogs treated with ABT-510; thus, toxicities seen with combination therapy are attributed to ABT-751.
Thin Horzontal Rule









Pet owners seeking novel treatment options for animals with serious health conditions find an Animal Clinical Investigation network veterinarian participating in a clinical trial.
Animal Clinical Investigation network veterinarian and pet owner work together to determine whether the pet is eligible for the trial. Eligible pets begin treatment at an ACI network hospital.
Information from the trial is used to help develop new drugs and treatments, providing a source of hope for people whose pets face serious illnesses.